The first biosimilars were launched a decade ago, and are now facing their biggest battle yet as they take on Humira, the world’s best-selling drug.
Though the European launch of a few Humira biosimilars is not expected to do big damage to the arthritis and Crohn’s disease giant, biosimilars are now poised to alter price, access, and treatment pathways. Tap in to this examination of biosimilars as seen through the lens of Humira, and understand the questions of how biosimilars will be used, how payers will react, whether new pricing and payer models will be sustainable, and much more.
Though the European launch of a few Humira biosimilars is not expected to do big damage to the arthritis and Crohn’s disease giant, biosimilars are now poised to alter price, access, and treatment pathways. Tap in to this examination of biosimilars as seen through the lens of Humira, and understand the questions of how biosimilars will be used, how payers will react, whether new pricing and payer models will be sustainable, and much more.
